Patents Assigned to Virobay, Inc.
  • Publication number: 20110046406
    Abstract: The present invention relates to a process for the preparation of alkyl esters of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid, which are intermediates useful in the synthesis of (S)-N-(1-cyanocyclopropyl)-5-cyclopropyl-4,4-difluoro-2-(S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethylamino)pentanamide and related compounds, which are compounds that are cysteine protease inhibitors.
    Type: Application
    Filed: August 16, 2010
    Publication date: February 24, 2011
    Applicant: ViroBay, Inc.
    Inventors: Barry Hart, Jeff Dener, Michael Green, Michael Standen, Oldrich Kocian
  • Patent number: 7893112
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: February 22, 2011
    Assignee: Virobay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • Patent number: 7893093
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: February 22, 2011
    Assignee: ViroBay, Inc.
    Inventor: Craig J. Mossman
  • Publication number: 20100305331
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: February 23, 2010
    Publication date: December 2, 2010
    Applicant: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Publication number: 20100266537
    Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: October 23, 2009
    Publication date: October 21, 2010
    Applicant: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
  • Patent number: 7781487
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: August 24, 2010
    Assignee: ViroBay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • Patent number: 7737300
    Abstract: The present invention is directed to a process for preparing certain cysteine protease inhibitors.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: June 15, 2010
    Assignee: ViroBay, Inc.
    Inventor: Jiayao Li
  • Patent number: 7696250
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 13, 2010
    Assignee: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Patent number: 7662849
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: February 16, 2010
    Assignee: ViroBay, Inc.
    Inventors: John W. Patterson, Soon H. Woo
  • Publication number: 20090312571
    Abstract: The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides as well as novel compounds prepared or used in the process.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 17, 2009
    Applicant: ViroBay, Inc.
    Inventor: Jeffrey Dener
  • Publication number: 20090270415
    Abstract: The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
    Type: Application
    Filed: October 22, 2008
    Publication date: October 29, 2009
    Applicant: ViroBay, Inc.
    Inventors: Leslie Jean Holsinger, Kyle Elrod, John O. Link, Michael Graupe, In Jong Kim
  • Patent number: 7608592
    Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: October 27, 2009
    Assignee: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
  • Publication number: 20090234127
    Abstract: The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides, and their use in the preparation of HCV inhibitors and cathepsin inhibitors.
    Type: Application
    Filed: March 11, 2009
    Publication date: September 17, 2009
    Applicant: ViroBay, Inc.
    Inventor: Jeffrey Dener
  • Publication number: 20090233909
    Abstract: The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 17, 2009
    Applicant: Virobay, Inc.
    Inventors: Soon H. Woo, Randall W. Vivian, John O. Link
  • Publication number: 20090203629
    Abstract: The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 13, 2009
    Applicant: ViroBay, Inc.
    Inventor: Leslie Holsinger
  • Publication number: 20090170909
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: December 17, 2008
    Publication date: July 2, 2009
    Applicant: Virobay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Patent number: 7547701
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: June 16, 2009
    Assignee: Virobay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Soon H. Woo, Sheila M. Zipfel
  • Patent number: 7488848
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: February 10, 2009
    Assignee: Virobay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Publication number: 20090023781
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: December 1, 2005
    Publication date: January 22, 2009
    Applicant: Virobay, Inc.
    Inventor: Eduardo L. Setti
  • Publication number: 20080293819
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: April 1, 2008
    Publication date: November 27, 2008
    Applicant: ViroBay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu